Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada

Ahmad Shakeri; Kaleen N Hayes; Tara Gomes; Mina Tadrous

doi:10.3138/canlivj-2020-0041

Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada

Can Liver J. 2021 Nov 11;4(4):426-429. doi: 10.3138/canlivj-2020-0041. eCollection 2021 Fall.

Authors

Ahmad Shakeri¹, Kaleen N Hayes², Tara Gomes^{3

4

5}, Mina Tadrous^{1

3}

Affiliations

¹ Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
² Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
³ Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
⁴ Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
⁵ Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.

No abstract available

Keywords: Canada; antiviral; health policy; hepatitis C; prescription drugs.

Grants and funding

This study was funded by the Canadian Institutes of Health Research (CIHR) and the Health System Research Fund (HSRF) from the Ontario Ministry of Health.